WO2010096801A1 - Ligands des récepteurs aux oestrogènes et leurs procédés d'utilisation - Google Patents

Ligands des récepteurs aux oestrogènes et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2010096801A1
WO2010096801A1 PCT/US2010/025032 US2010025032W WO2010096801A1 WO 2010096801 A1 WO2010096801 A1 WO 2010096801A1 US 2010025032 W US2010025032 W US 2010025032W WO 2010096801 A1 WO2010096801 A1 WO 2010096801A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
testosterone
total serum
serum testosterone
levels
Prior art date
Application number
PCT/US2010/025032
Other languages
English (en)
Inventor
James T. Dalton
Mitchell S. Steiner
Original Assignee
Gtx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020157033005A priority Critical patent/KR20150135547A/ko
Priority to MX2011008879A priority patent/MX340753B/es
Priority to CN201080017935.0A priority patent/CN102413692B/zh
Priority to KR1020117022324A priority patent/KR101458539B1/ko
Priority to AU2010215809A priority patent/AU2010215809B2/en
Priority to CA2753436A priority patent/CA2753436C/fr
Priority to EP10744458A priority patent/EP2398322A4/fr
Priority to RU2011137324/15A priority patent/RU2543339C2/ru
Application filed by Gtx, Inc. filed Critical Gtx, Inc.
Priority to JP2011551292A priority patent/JP5611991B2/ja
Priority to KR1020137020249A priority patent/KR20130101146A/ko
Publication of WO2010096801A1 publication Critical patent/WO2010096801A1/fr
Priority to IL214805A priority patent/IL214805A0/en
Priority to US13/215,679 priority patent/US9427418B2/en
Priority to US14/523,333 priority patent/US9624161B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pain & Pain Management (AREA)

Abstract

La présente invention concerne des procédés permettant de réduire les taux de testostérone grâce à une réduction des taux d'hormone lutéinisante (LH) ou des taux indépendants de LH chez un sujet masculin, ainsi que des méthodes permettant de traiter, d'inhiber, de réduire l'incidence, de réduire la gravité ou d'inhiber un cancer de la prostate avancé et, également, un traitement palliatif du cancer de la prostate avancé.
PCT/US2010/025032 2009-02-23 2010-02-23 Ligands des récepteurs aux oestrogènes et leurs procédés d'utilisation WO2010096801A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
EP10744458A EP2398322A4 (fr) 2009-02-23 2010-02-23 Ligands des récepteurs aux oestrogènes et leurs procédés d'utilisation
CN201080017935.0A CN102413692B (zh) 2009-02-23 2010-02-23 雌激素受体配体及其使用方法
KR1020117022324A KR101458539B1 (ko) 2009-02-23 2010-02-23 에스트로겐 수용체 리간드 및 그 이용 방법
AU2010215809A AU2010215809B2 (en) 2009-02-23 2010-02-23 Estrogen receptor ligands and methods of use thereof
CA2753436A CA2753436C (fr) 2009-02-23 2010-02-23 Ligands des recepteurs aux oestrogenes et leurs procedes d'utilisation
KR1020157033005A KR20150135547A (ko) 2009-02-23 2010-02-23 에스트로겐 수용체 리간드 및 그 이용 방법
RU2011137324/15A RU2543339C2 (ru) 2009-02-23 2010-02-23 Лиганды рецепторов эстрогенов и способы их применения
MX2011008879A MX340753B (es) 2009-02-23 2010-02-23 Ligandos de receptor de estrogeno y metodos de uso de los mismos.
JP2011551292A JP5611991B2 (ja) 2009-02-23 2010-02-23 Ａｄｔのための医薬の製造におけるエストロゲン受容体リガンドの使用方法
KR1020137020249A KR20130101146A (ko) 2009-02-23 2010-02-23 에스트로겐 수용체 리간드 및 그 이용 방법
IL214805A IL214805A0 (en) 2009-02-23 2011-08-23 Estrogen receptor ligands and methods of use thereof
US13/215,679 US9427418B2 (en) 2009-02-23 2011-08-23 Estrogen receptor ligands and methods of use thereof
US14/523,333 US9624161B2 (en) 2009-02-23 2014-10-24 Estrogen receptor ligands and methods of use thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15470709P 2009-02-23 2009-02-23
US61/154,707 2009-02-23
US16898309P 2009-04-14 2009-04-14
US61/168,983 2009-04-14
US26166909P 2009-11-16 2009-11-16
US61/261,669 2009-11-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/215,679 Continuation-In-Part US9427418B2 (en) 2009-02-23 2011-08-23 Estrogen receptor ligands and methods of use thereof

Publications (1)

Publication Number Publication Date
WO2010096801A1 true WO2010096801A1 (fr) 2010-08-26

Family

ID=42634248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/025032 WO2010096801A1 (fr) 2009-02-23 2010-02-23 Ligands des récepteurs aux oestrogènes et leurs procédés d'utilisation

Country Status (10)

Country Link
EP (1) EP2398322A4 (fr)
JP (1) JP5611991B2 (fr)
KR (3) KR20150135547A (fr)
CN (1) CN102413692B (fr)
BR (1) BR112014004008A2 (fr)
CA (1) CA2753436C (fr)
IL (1) IL214805A0 (fr)
MX (1) MX340753B (fr)
RU (1) RU2543339C2 (fr)
WO (1) WO2010096801A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141630A1 (fr) * 2009-06-03 2010-12-09 University Of Southern California Compositions et méthodes de traitement du cancer faisant appel à la perturbation de la voie de signalisation lh/lhr
WO2013142390A1 (fr) * 2012-03-21 2013-09-26 Gtx, Inc. Inhibiteurs de la sous-famille 1c3 d'aldo-céto réductase (akr1c3)
WO2014039820A1 (fr) * 2012-09-07 2014-03-13 Gtx, Inc. Inhibiteurs de la sous-famille 1c3 de l'aldo-céto réductase (akr1c3)
CN103957706A (zh) * 2011-08-23 2014-07-30 Gtx公司 雌激素受体配体以及其使用方法
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2023220117A1 (fr) * 2022-05-10 2023-11-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Méthodes de traitement d'une cardiomyopathie dilatée et d'une insuffisance cardiaque

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192310A1 (en) * 2001-02-02 2002-12-19 Bland Jeffrey S. Medical composition for managing hormone balance
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
US20060287359A1 (en) * 2003-08-08 2006-12-21 Richmond Danso-Danquah Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
US20070265296A1 (en) * 2005-11-28 2007-11-15 Dalton James T Nuclear receptor binding agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EA201500845A1 (ru) * 2005-11-28 2016-04-29 Джи Ти Икс, ИНК. Агенты, связывающиеся с ядерными рецепторами

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192310A1 (en) * 2001-02-02 2002-12-19 Bland Jeffrey S. Medical composition for managing hormone balance
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
US20060287359A1 (en) * 2003-08-08 2006-12-21 Richmond Danso-Danquah Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
US20070265296A1 (en) * 2005-11-28 2007-11-15 Dalton James T Nuclear receptor binding agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2398322A4 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2010141630A1 (fr) * 2009-06-03 2010-12-09 University Of Southern California Compositions et méthodes de traitement du cancer faisant appel à la perturbation de la voie de signalisation lh/lhr
US8680055B2 (en) 2009-06-03 2014-03-25 University Of Southern California Methods for decreasing steroidogenesis in prostate cancer cells
CN103957706A (zh) * 2011-08-23 2014-07-30 Gtx公司 雌激素受体配体以及其使用方法
JP2014524479A (ja) * 2011-08-23 2014-09-22 ジーティーエックス・インコーポレイテッド エストロゲン受容体リガンドおよびその使用方法
WO2013142390A1 (fr) * 2012-03-21 2013-09-26 Gtx, Inc. Inhibiteurs de la sous-famille 1c3 d'aldo-céto réductase (akr1c3)
WO2014039820A1 (fr) * 2012-09-07 2014-03-13 Gtx, Inc. Inhibiteurs de la sous-famille 1c3 de l'aldo-céto réductase (akr1c3)
WO2023220117A1 (fr) * 2022-05-10 2023-11-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Méthodes de traitement d'une cardiomyopathie dilatée et d'une insuffisance cardiaque

Also Published As

Publication number Publication date
EP2398322A4 (fr) 2012-12-05
CN102413692B (zh) 2015-01-07
CA2753436C (fr) 2016-05-24
KR20130101146A (ko) 2013-09-12
MX2011008879A (es) 2012-04-30
MX340753B (es) 2016-07-25
JP2012518654A (ja) 2012-08-16
KR20150135547A (ko) 2015-12-02
AU2010215809A1 (en) 2011-09-22
JP5611991B2 (ja) 2014-10-22
RU2011137324A (ru) 2013-03-27
CA2753436A1 (fr) 2010-08-26
BR112014004008A2 (pt) 2017-03-28
KR101458539B1 (ko) 2014-11-10
CN102413692A (zh) 2012-04-11
KR20110131227A (ko) 2011-12-06
IL214805A0 (en) 2011-11-30
RU2543339C2 (ru) 2015-02-27
EP2398322A1 (fr) 2011-12-28

Similar Documents

Publication Publication Date Title
CA2753436C (fr) Ligands des recepteurs aux oestrogenes et leurs procedes d'utilisation
US9051267B2 (en) Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) Estrogen receptor ligands and methods of use thereof
EP3285757B1 (fr) Ligands de composés dégradant des récepteurs d'androgènes sélectifs (sard) et leurs méthodes d'utilisation
US11591290B2 (en) Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US20140187641A1 (en) Estrogen receptor ligands and methods of use thereof
US9409856B2 (en) Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) Estrogen receptor ligands and methods of use thereof
US20140057985A1 (en) Estrogen receptor ligands and methods of use thereof
AU2012312902B2 (en) Estrogen receptor ligands and methods of use thereof
AU2010215809B2 (en) Estrogen receptor ligands and methods of use thereof
US20140057946A1 (en) Estrogen receptor ligands and methods of use thereof
WO2013043304A9 (fr) Ligands de récepteur d'œstrogène et procédés pour les utiliser
WO2020073017A1 (fr) Ligands de composés de dégradation sélectifs de récepteurs des androgènes (sard) et leurs méthodes d'utilisation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080017935.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10744458

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2753436

Country of ref document: CA

Ref document number: 2011551292

Country of ref document: JP

Ref document number: 214805

Country of ref document: IL

Ref document number: MX/A/2011/008879

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2010215809

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 7150/DELNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2010215809

Country of ref document: AU

Date of ref document: 20100223

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20117022324

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2010744458

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011137324

Country of ref document: RU

Ref document number: 2010744458

Country of ref document: EP